Abstract:BACKGROUNDA range of protein-based nanoparticles has been developed for cancer drug delivery and diagnostics. This includes the E2 protein derived from the pyruvate dehydrogenase complex in Geobacillus stearothermophilus which assembles into a 60-subunit protein cage structure that is capable of encapsulating cancer therapeutics. In this study antibody fragments targeting the epidermal growth factor receptor (EGFR) were tethered to the surface of E2 protein nanoparticles to determine whether the protein nanoparticles could be specifically targeted to EGFR overexpressing cancer cells.RESULTSVariants of the anti-EGFR antibody fragment and the E2 protein containing specific cysteine residues (E2N17A186C) were conjugated using a maleimide-specific crosslinker. Electron microscopy and dynamic light scattering analysis indicated that the cysteine modified E2 protein correctly assembled into a 25-30nm particle. The conjugation of the anti-EGFR antibody fragment (26 kDa) with a subunit of the E2 protein (26 kDa) was confirmed by mass spectrometry with an estimated molecular weight of 52 kDa. The binding of the conjugated E2 particle to native EGFR on MDA MB 231 cells and recombinant EGFR was confirmed using flow cytometry and biolayer interferometry, respectively.CONCLUSIONSIn this study, proof-of-principle that an EGFR-targeting scFv can be stably conjugated to the cysteine variant E2N17A186C protein nanoparticle without loss of targeting capability has been demonstrated. Conceptually scFv antibody fragments reactive with other important cancer targets could be utilized and presents the opportunity for generation of multi-targeted protein nanoparticles by conjugating various scFvs with different specificities on the same particle. (c) 2014 Society of Chemical Industry

Prokaryotic expression and refolding of EGFR extracellular domain and generation of phage display human scFv against EGFR.

Rational design of an EGF-IL18 fusion protein: implication for developing tumor therapeutics.

AN ANTI-TUMOR RESEARCH OF RECOMBINANT PHAGE VACCINE EXPRESSED XENOGENIC EGFR

Immunotherapy of EGFR-positive Tumor Based on Recombinant EGFR Phage Vaccine

[Immunotherapeutic Effect of Recombinant EGFR Phage Vaccine on Tumors].

Selection and characterization of an internalizing epidermal-growth-factor-receptor antibody.

[Expression, Purification and Refolding of Extracellular Domain of Mouse Epidermal Growth Factor Receptor].

The Construction of Anti-EGFR Single Chain Variable Fragment Fused with Gelonin Toxin Prokaryotic Expressing Plasmid and the Study of Its Anti-tumor Effects

Expression and purification of the human epidermal growth factor receptor extracellular domain

Expression of Intracellular Domain of Epidermal Growth Factor Receptor and Generation of Its Monoclonal Antibody

Preparation and characterization of human anti-EGFR scFv-protamine fusion protein

Prokaryotic Expression of Extracellular Domain of Human EGFR and It's Immunogenity

Synthesis and purification of a toxin-linked conjugate targeting epidermal growth factor receptor in Escherichia coli.

Renaturing and Antigenic Identification of Human EGF Receptor Extracellular Domain Inclusion Body Overexpressed in Escherichia Coli

Construction and Screening of Phage Antibody Libraries Against Epidermal Growth Factor Receptor Variant Type Ⅲ

Isolation of Scfvs to in Vitro Produced Extracellular Domains of EGFR Family Members.

Development of A Protein Nanoparticle Platform for Targeting Egfr Expressing Cancer Cells

Cloning and expression of a novel target fusion protein and its application in anti-tumor therapy

Expression of xenogentic epidermal growth factor receptor ectodomain and its antitumor effect]

[Construction of a Phage Antibody Library and Screening of Anti-Epidermal Growth Factor Receptor Variant III Single Chain Antibody].

Analysis of the in vitro function and internalization ability of a humanized EGFR antibody AE01 expressed by Chinese hamster ovary cells